Literature DB >> 9453529

Improvement in the mechanical efficiency of walking: an explanation for the "placebo effect" seen during repeated exercise testing of patients with heart failure. Duke University Clinical Cardiology Studies (DUCCS) Exercise Group.

S D Russell1, F R McNeer, P A Beere, L J Logan, M B Higginbotham.   

Abstract

To determine the mechanism responsible for the "placebo effect" seen during serial exercise testing of patients with heart failure, we examined metabolic variables for 81 patients who underwent five baseline exercise tests as part of a multicenter drug trial. The patients were 50 men and 31 women with a mean ejection fraction of 30.1% and a mean age of 69 years. From test 1 to 2, the exercise time increased from 419 +/- 140 to 462 +/- 130 seconds before it reached a plateau over the next three tests. Metabolic measurements at test 1 and test 3 revealed no change in peak oxygen consumption ( 1119 +/- 376 to 1105 +/- 346 ml/min). Maximum heart rate, systolic blood pressure, ventilation, and respiratory exchange ratio also were unchanged. The onset of the anaerobic threshold was delayed from 211 +/- 81 to 238 +/- 93 seconds, but there was no change in oxygen consumption at the anaerobic threshold (810 +/- 222 to 795 +/- 220 ml/min). At a predetermined submaximal level, oxygen consumption, ventilation, and respiratory exchange ratio all decreased to a statistically significant degree. These results indicate that a rapid increase in the mechanical efficiency of walking contributes to the placebo effect among patients with heart failure during serial exercise testing and is independent of changes in conditioning or motivation.

Entities:  

Mesh:

Year:  1998        PMID: 9453529     DOI: 10.1016/s0002-8703(98)70350-3

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  4 in total

1.  Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2).

Authors:  Benjamin W Van Tassell; Leo F Buckley; Salvatore Carbone; Cory R Trankle; Justin M Canada; Dave L Dixon; Nayef Abouzaki; Claudia Oddi-Erdle; Giuseppe Biondi-Zoccai; Ross Arena; Antonio Abbate
Journal:  Clin Cardiol       Date:  2017-05-05       Impact factor: 2.882

2.  Pharmacokinetics and Pharmacodynamics of Inorganic Nitrate in Heart Failure With Preserved Ejection Fraction.

Authors:  Payman Zamani; Victor Tan; Haideliza Soto-Calderon; Melissa Beraun; Jeffrey A Brandimarto; Lien Trieu; Swapna Varakantam; Paschalis-Thomas Doulias; Raymond R Townsend; Jesse Chittams; Kenneth B Margulies; Thomas P Cappola; David C Poole; Harry Ischiropoulos; Julio A Chirinos
Journal:  Circ Res       Date:  2016-12-07       Impact factor: 17.367

3.  Variables Measured During Cardiopulmonary Exercise Testing as Predictors of Mortality in Chronic Systolic Heart Failure.

Authors:  Steven J Keteyian; Mahesh Patel; William E Kraus; Clinton A Brawner; Timothy R McConnell; Ileana L Piña; Eric S Leifer; Jerome L Fleg; Gordon Blackburn; Gregg C Fonarow; Paul J Chase; Lucy Piner; Marianne Vest; Christopher M O'Connor; Jonathan K Ehrman; Mary N Walsh; Gregory Ewald; Dan Bensimhon; Stuart D Russell
Journal:  J Am Coll Cardiol       Date:  2016-02-23       Impact factor: 24.094

4.  Reproducibility of peak oxygen uptake and other cardiopulmonary exercise testing parameters in patients with heart failure (from the Heart Failure and A Controlled Trial Investigating Outcomes of exercise traiNing).

Authors:  Daniel R Bensimhon; Eric S Leifer; Stephen J Ellis; Jerome L Fleg; Steven J Keteyian; Ileana L Piña; Dalane W Kitzman; Robert S McKelvie; William E Kraus; Daniel E Forman; Andrew J Kao; David J Whellan; Christopher M O'Connor; Stuart D Russell
Journal:  Am J Cardiol       Date:  2008-07-09       Impact factor: 2.778

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.